COFCO Biotechnology Co., Ltd. Logo

COFCO Biotechnology Co., Ltd.

000930.SZ

(1.5)
Stock Price

5,84 CNY

-1.17% ROA

-1.95% ROE

-55.69x PER

Market Cap.

11.381.486.400,00 CNY

50.72% DER

0% Yield

-0.98% NPM

COFCO Biotechnology Co., Ltd. Stock Analysis

COFCO Biotechnology Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

COFCO Biotechnology Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (40%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

3 PBV

The stock's PBV ratio (1.16x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

4 Dividend Growth

The company's dividend growth has shown a positive trajectory over the past three years, consistently increasing year after year, indicating a favorable trend for potential investors.

5 ROE

The stock's ROE indicates a negative return (-2.25%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-1.56%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-501) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

COFCO Biotechnology Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

COFCO Biotechnology Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

COFCO Biotechnology Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

COFCO Biotechnology Co., Ltd. Revenue
Year Revenue Growth
1996 102.200.397
1997 229.005.236 55.37%
1998 345.643.004 33.75%
1999 482.901.137 28.42%
2000 705.181.140 31.52%
2001 853.171.163 17.35%
2002 1.199.416.136 28.87%
2003 1.547.358.446 22.49%
2004 2.198.247.382 29.61%
2005 3.261.313.574 32.6%
2006 4.398.173.911 25.85%
2007 4.178.145.874 -5.27%
2008 4.801.867.703 12.99%
2009 5.011.011.162 4.17%
2010 5.967.193.720 16.02%
2011 7.401.292.582 19.38%
2012 7.730.371.836 4.26%
2013 7.339.863.856 -5.32%
2014 7.153.196.656 -2.61%
2015 6.457.283.434 -10.78%
2016 5.603.374.518 -15.24%
2017 6.275.914.087 10.72%
2018 17.703.930.046 64.55%
2019 19.471.955.122 9.08%
2020 19.909.350.658 2.2%
2021 23.468.553.115 15.17%
2022 19.918.051.356 -17.83%
2023 21.644.479.830 7.98%
2023 20.289.836.489 -6.68%
2024 20.616.908.760 1.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

COFCO Biotechnology Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 20.890.311 100%
2011 18.887.819 -10.6%
2012 14.456.655 -30.65%
2013 14.111.812 -2.44%
2014 13.498.962 -4.54%
2015 6.963.274 -93.86%
2016 18.514.779 62.39%
2017 27.008.485 31.45%
2018 96.266.958 71.94%
2019 87.151.319 -10.46%
2020 113.672.793 23.33%
2021 119.277.453 4.7%
2022 132.862.554 10.22%
2023 158.062.179 15.94%
2023 161.937.289 2.39%
2024 205.906.968 21.35%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

COFCO Biotechnology Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 5.879.298
1997 9.791.684 39.96%
1998 10.846.582 9.73%
1999 16.952.539 36.02%
2000 38.245.848 55.67%
2001 35.507.670 -7.71%
2002 50.702.102 29.97%
2003 46.536.727 -8.95%
2004 83.940.327 44.56%
2005 101.671.096 17.44%
2006 254.792.074 60.1%
2007 207.849.607 -22.58%
2008 278.272.823 25.31%
2009 250.450.256 -11.11%
2010 70.064.198 -257.46%
2011 91.219.367 23.19%
2012 73.164.893 -24.68%
2013 47.866.652 -52.85%
2014 50.422.418 5.07%
2015 76.404.633 34.01%
2016 147.297.650 48.13%
2017 100.683.097 -46.3%
2018 217.909.413 53.8%
2019 179.401.560 -21.46%
2020 129.232.868 -38.82%
2021 153.908.624 16.03%
2022 147.568.421 -4.3%
2023 1.399.683.356 89.46%
2023 124.936.874 -1020.31%
2024 -310.456.206 140.24%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

COFCO Biotechnology Co., Ltd. EBITDA
Year EBITDA Growth
1996 23.088.466
1997 41.298.092 44.09%
1998 55.618.939 25.75%
1999 73.934.735 24.77%
2000 155.762.833 52.53%
2001 184.854.498 15.74%
2002 255.227.949 27.57%
2003 281.458.347 9.32%
2004 385.904.160 27.07%
2005 550.051.083 29.84%
2006 175.989.322 -212.55%
2007 596.923.472 70.52%
2008 600.260.184 0.56%
2009 966.422.758 37.89%
2010 825.898.794 -17.01%
2011 1.012.272.571 18.41%
2012 716.987.429 -41.18%
2013 498.617.992 -43.79%
2014 481.674.677 -3.52%
2015 -276.035.588 274.5%
2016 557.911.805 149.48%
2017 669.156.804 16.62%
2018 1.994.227.301 66.45%
2019 2.081.690.677 4.2%
2020 1.631.891.505 -27.56%
2021 2.372.915.515 31.23%
2022 2.238.809.191 -5.99%
2023 589.659.458 -279.68%
2023 53.777.630 -996.48%
2024 763.593.000 92.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

COFCO Biotechnology Co., Ltd. Gross Profit
Year Gross Profit Growth
1996 32.719.069
1997 59.466.064 44.98%
1998 76.834.798 22.61%
1999 101.064.677 23.97%
2000 201.267.205 49.79%
2001 193.106.904 -4.23%
2002 245.183.525 21.24%
2003 286.484.720 14.42%
2004 391.093.961 26.75%
2005 339.361.670 -15.24%
2006 -26.390.062 1385.94%
2007 -292.898.407 90.99%
2008 -63.055.213 -364.51%
2009 258.640.155 124.38%
2010 208.675.945 -23.94%
2011 706.214.499 70.45%
2012 774.855.336 8.86%
2013 687.192.190 -12.76%
2014 690.097.112 0.42%
2015 -24.964.006 2864.37%
2016 772.549.089 103.23%
2017 679.404.851 -13.71%
2018 2.900.478.525 76.58%
2019 2.736.450.332 -5.99%
2020 2.081.655.067 -31.46%
2021 2.625.704.355 20.72%
2022 2.251.468.163 -16.62%
2023 1.478.320.413 -52.3%
2023 948.400.318 -55.88%
2024 1.479.473.580 35.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

COFCO Biotechnology Co., Ltd. Net Profit
Year Net Profit Growth
1996 16.174.680
1997 29.329.015 44.85%
1998 36.469.244 19.58%
1999 40.641.186 10.27%
2000 86.024.638 52.76%
2001 109.977.606 21.78%
2002 110.173.556 0.18%
2003 98.796.330 -11.52%
2004 101.137.150 2.31%
2005 139.063.512 27.27%
2006 -384.841.069 136.14%
2007 25.758.639 1594.03%
2008 26.403.152 2.44%
2009 251.921.290 89.52%
2010 263.882.865 4.53%
2011 355.074.338 25.68%
2012 182.987.631 -94.04%
2013 50.717.547 -260.8%
2014 35.231.783 -43.95%
2015 -1.418.036.826 102.48%
2016 127.078.702 1215.87%
2017 237.307.176 46.45%
2018 483.042.529 50.87%
2019 592.821.396 18.52%
2020 593.116.803 0.05%
2021 1.129.602.966 47.49%
2022 1.058.529.324 -6.71%
2023 9.506.793 -11034.45%
2023 -601.629.843 101.58%
2024 146.565.576 510.49%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

COFCO Biotechnology Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -1 100%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 0%
2022 1 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

COFCO Biotechnology Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 12.277.404
1999 -315.801.935 103.89%
2000 -33.554.786 -841.15%
2001 -586.431.233 94.28%
2002 -313.124.301 -87.28%
2003 -646.548.871 51.57%
2004 -365.119.758 -77.08%
2005 -340.981.597 -7.08%
2006 -373.045.009 8.6%
2007 748.131.339 149.86%
2008 194.822.400 -284.01%
2009 427.013.435 54.38%
2010 134.874.129 -216.6%
2011 543.976.326 75.21%
2012 107.993.183 -403.71%
2013 497.110.042 78.28%
2014 77.227.855 -543.69%
2015 -198.062.086 138.99%
2016 624.152.713 131.73%
2017 108.434.325 -475.6%
2018 -1.791.661.286 106.05%
2019 2.748.944.715 165.18%
2020 -3.898.371.336 170.52%
2021 3.731.816.551 204.46%
2022 142.662.668 -2515.83%
2023 2.272.003.612 93.72%
2023 1.328.953.290 -70.96%
2024 289.411.048 -359.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

COFCO Biotechnology Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 19.499.351
1999 -144.209.589 113.52%
2000 126.837.414 213.7%
2001 91.714.724 -38.3%
2002 190.142.953 51.77%
2003 144.379.931 -31.7%
2004 338.254.265 57.32%
2005 385.157.112 12.18%
2006 71.710.361 -437.1%
2007 1.085.323.447 93.39%
2008 438.725.961 -147.38%
2009 589.445.800 25.57%
2010 313.296.449 -88.14%
2011 693.886.298 54.85%
2012 268.695.623 -158.24%
2013 737.712.318 63.58%
2014 206.776.195 -256.77%
2015 -114.172.074 281.11%
2016 784.676.104 114.55%
2017 747.682.721 -4.95%
2018 -923.311.085 180.98%
2019 3.649.709.320 125.3%
2020 -2.910.855.638 225.38%
2021 4.841.590.965 160.12%
2022 708.442.677 -583.41%
2023 2.426.086.951 70.8%
2023 1.963.469.023 -23.56%
2024 351.466.627 -458.65%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

COFCO Biotechnology Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 7.221.947
1999 171.592.346 95.79%
2000 160.392.200 -6.98%
2001 678.145.957 76.35%
2002 503.267.254 -34.75%
2003 790.928.802 36.37%
2004 703.374.023 -12.45%
2005 726.138.709 3.14%
2006 444.755.370 -63.27%
2007 337.192.108 -31.9%
2008 243.903.560 -38.25%
2009 162.432.365 -50.16%
2010 178.422.320 8.96%
2011 149.909.971 -19.02%
2012 160.702.439 6.72%
2013 240.602.275 33.21%
2014 129.548.339 -85.72%
2015 83.890.012 -54.43%
2016 160.523.391 47.74%
2017 639.248.396 74.89%
2018 868.350.201 26.38%
2019 900.764.604 3.6%
2020 987.515.698 8.78%
2021 1.109.774.414 11.02%
2022 565.780.009 -96.15%
2023 154.083.339 -267.19%
2023 634.515.733 75.72%
2024 62.055.579 -922.5%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

COFCO Biotechnology Co., Ltd. Equity
Year Equity Growth
1996 67.859.811
1997 98.988.827 31.45%
1998 150.281.595 34.13%
1999 571.943.572 73.72%
2000 592.081.799 3.4%
2001 1.380.561.067 57.11%
2002 1.506.007.440 8.33%
2003 1.611.868.164 6.57%
2004 1.788.054.934 9.85%
2005 2.435.043.982 26.57%
2006 2.021.100.251 -20.48%
2007 1.912.075.234 -5.7%
2008 2.034.466.055 6.02%
2009 2.341.700.338 13.12%
2010 2.601.724.339 9.99%
2011 2.938.706.447 11.47%
2012 3.069.127.704 4.25%
2013 3.093.496.825 0.79%
2014 3.103.769.693 0.33%
2015 1.573.741.699 -97.22%
2016 1.705.820.401 7.74%
2017 1.961.343.974 13.03%
2018 9.645.844.523 79.67%
2019 10.202.908.356 5.46%
2020 10.801.794.821 5.54%
2021 11.758.696.579 8.14%
2022 12.511.499.191 6.02%
2023 10.853.572.207 -15.28%
2023 11.063.318.165 1.9%
2024 10.849.673.854 -1.97%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

COFCO Biotechnology Co., Ltd. Assets
Year Assets Growth
1996 190.645.617
1997 307.607.049 38.02%
1998 490.576.563 37.3%
1999 1.080.302.199 54.59%
2000 1.351.920.211 20.09%
2001 2.447.801.197 44.77%
2002 3.040.111.650 19.48%
2003 4.717.090.670 35.55%
2004 5.899.967.284 20.05%
2005 7.392.499.161 20.19%
2006 7.688.459.119 3.85%
2007 7.646.595.191 -0.55%
2008 7.204.071.493 -6.14%
2009 6.766.654.910 -6.46%
2010 6.922.905.592 2.26%
2011 6.477.364.373 -6.88%
2012 6.859.129.171 5.57%
2013 6.551.388.260 -4.7%
2014 6.864.197.920 4.56%
2015 5.648.209.570 -21.53%
2016 5.435.006.590 -3.92%
2017 5.955.889.252 8.75%
2018 20.287.580.873 70.64%
2019 17.156.862.702 -18.25%
2020 20.484.494.619 16.24%
2021 18.062.119.861 -13.41%
2022 18.100.294.856 0.21%
2023 16.557.861.385 -9.32%
2023 17.435.053.890 5.03%
2024 18.446.400.676 5.48%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

COFCO Biotechnology Co., Ltd. Liabilities
Year Liabilities Growth
1996 122.785.806
1997 208.618.222 41.14%
1998 340.294.967 38.69%
1999 508.358.626 33.06%
2000 759.838.411 33.1%
2001 1.067.240.130 28.8%
2002 1.534.104.209 30.43%
2003 3.105.222.505 50.6%
2004 4.111.912.349 24.48%
2005 4.957.455.179 17.06%
2006 5.667.358.867 12.53%
2007 5.734.519.956 1.17%
2008 5.169.605.437 -10.93%
2009 4.424.954.571 -16.83%
2010 4.321.181.251 -2.4%
2011 3.538.657.926 -22.11%
2012 3.790.001.465 6.63%
2013 3.457.891.434 -9.6%
2014 3.760.428.226 8.05%
2015 4.074.467.871 7.71%
2016 3.729.186.189 -9.26%
2017 3.994.545.277 6.64%
2018 10.641.736.349 62.46%
2019 6.953.954.345 -53.03%
2020 9.682.699.797 28.18%
2021 6.303.423.281 -53.61%
2022 5.588.795.664 -12.79%
2023 5.634.280.244 0.81%
2023 6.371.735.725 11.57%
2024 7.502.368.051 15.07%

COFCO Biotechnology Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
11.21
Net Income per Share
-0.11
Price to Earning Ratio
-55.69x
Price To Sales Ratio
0.54x
POCF Ratio
5.54
PFCF Ratio
7.25
Price to Book Ratio
1.09
EV to Sales
0.73
EV Over EBITDA
45.51
EV to Operating CashFlow
7.38
EV to FreeCashFlow
9.69
Earnings Yield
-0.02
FreeCashFlow Yield
0.14
Market Cap
11,38 Bil.
Enterprise Value
15,21 Bil.
Graham Number
3.73
Graham NetNet
-1.57

Income Statement Metrics

Net Income per Share
-0.11
Income Quality
-10.05
ROE
-0.02
Return On Assets
-0.01
Return On Capital Employed
-0.01
Net Income per EBT
1.78
EBT Per Ebit
0.84
Ebit per Revenue
-0.01
Effective Tax Rate
-0.71

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.06
Operating Profit Margin
-0.01
Pretax Profit Margin
-0.01
Net Profit Margin
-0.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-8.43
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.1
Free CashFlow per Share
0.84
Capex to Operating CashFlow
0.24
Capex to Revenue
0.02
Capex to Depreciation
3.25
Return on Invested Capital
-0.01
Return on Tangible Assets
-0.01
Days Sales Outstanding
27.74
Days Payables Outstanding
12.76
Days of Inventory on Hand
63.17
Receivables Turnover
13.16
Payables Turnover
28.6
Inventory Turnover
5.78
Capex per Share
0.26

Balance Sheet

Cash per Share
0,90
Book Value per Share
5,87
Tangible Book Value per Share
5.35
Shareholders Equity per Share
5.61
Interest Debt per Share
2.9
Debt to Equity
0.51
Debt to Assets
0.29
Net Debt to EBITDA
11.44
Current Ratio
1.15
Tangible Asset Value
9,97 Bil.
Net Current Asset Value
0,56 Bil.
Invested Capital
10546322616
Working Capital
1,03 Bil.
Intangibles to Total Assets
0.05
Average Receivables
1,31 Bil.
Average Payables
0,69 Bil.
Average Inventory
3396791287
Debt to Market Cap
0.47

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

COFCO Biotechnology Co., Ltd. Dividends
Year Dividends Growth
2000 0
2002 0 0%
2004 0 0%
2005 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 1 0%

COFCO Biotechnology Co., Ltd. Profile

About COFCO Biotechnology Co., Ltd.

COFCO Biotechnology Co., Ltd. engages in the processing and production of agricultural products in China. The company offers edible corn, special, waxy corn, and modified waxy corn starch; Feed ingredients, such as corn gluten meal, sprayed corn husk, corn germ meal, DDGS, fertilizer raw materials and glutamic acid residue; fructose and functional sugar alcohol; fuel ethanol and edible alcohol; and monosodium glutamate, citric acid, potassium citrate, polylactic acid, phytosterols, and natural vitamin E. It also offers corn crude oil, edible liquid carbon dioxide, corn fiber feed, bacterial protein, microorganisms, compound antioxidant, nutritious health food; fructose, maltose, glucose, oligomeric isomalt, and beer syrups; plastic woven bags, plastic barrels, container bags and other plastic packaging products, valve-mouth paper bags, and other paper packaging products; liquors; and corn germ, rapeseed, peanut, soybean, and other edible oils, as well as warehousing and logistics, and information consulting services. In addition, the company is also involved in the research and development of biological engineering; production and sales of amino acids, compound fertilizers, and organic fertilizers; sales of chemical products and grains; wholesale and retail of edible agricultural products; export of products and related technologies of the company; import and export of raw and auxiliary materials, instruments and meters, mechanical equipment, and related technologies required for production; production and sales of steam; wholesale of coal; production, management, and sale of food and food additives; house leasing; food purchase; power generation; provision of pre-packaged food and bulk food, and dairy products; and wholesale and retail activity. The company was formerly known as COFCO Biochemical (Anhui) Co., Ltd. and changed its name to COFCO Biotechnology Co., Ltd. in September 2019. COFCO Biotechnology Co., Ltd. was founded in 1998 and is based in Bengbu, China.

CEO
Mr. De Guo Zhang
Employee
7.642
Address
No. 1, Zhongliang Avenue
Bengbu, 233010

COFCO Biotechnology Co., Ltd. Executives & BODs

COFCO Biotechnology Co., Ltd. Executives & BODs
# Name Age
1 Mr. Xichun Pan
Board Secretary
70
2 Mr. De Guo Zhang
GM & Non-Independent Director
70

COFCO Biotechnology Co., Ltd. Competitors